{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:09:06Z","timestamp":1793869746010,"version":"4.6.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de recherche du Qu\u00e9bec \u2013 Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"publisher","award":["24AARF-1192364"],"award-info":[{"award-number":["24AARF-1192364"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1RF1AG059789"],"award-info":[{"award-number":["1RF1AG059789"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rainwater Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Preclinical studies assessing drugs for Alzheimer\u2019s disease (AD) are conducted in animal models that usually display only one neuropathological feature of AD, whereas patients present with a complex combination of comorbidities and neuropathologies. Importantly, it is well established that amyloid-\u03b2 (A\u03b2) plaque and tau tangle accumulation interact in a phase-dependent manner, making it difficult to predict how targeting one might influence the other, as well as downstream degeneration.<\/jats:p>\n               <jats:p>We developed a transgenic mouse model, APP\/PS1xTau22, with progressive cortical A\u03b2 deposition and hippocampal tau neurofibrillary inclusions, to investigate how both neuropathologies act jointly to bring about neural degeneration, synapse loss and glial phenotypes. We then assessed whether applying murine chimeric aducanumab, an anti-amyloid immunotherapy, could impact the synergistic relationship between amyloid and tau.<\/jats:p>\n               <jats:p>Drug treatment resulted in a \u223c70% reduction in A\u03b2 deposition in hippocampal and cortical areas and produced a robust peri-plaque microglial and astrocytic response. Removing amyloid from the brain did not reverse or slow tau pathology or alter synapse loss.<\/jats:p>\n               <jats:p>Our findings suggest that, once the interaction between amyloid and tau is set in motion, reducing plaque burden by A\u03b2 immunotherapy may stimulate glial responses, but is insufficient to curb degenerative phenotypes in this model.<\/jats:p>","DOI":"10.1093\/brain\/awae345","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T21:34:01Z","timestamp":1730928841000},"page":"1316-1328","source":"Crossref","is-referenced-by-count":17,"title":["Tau, synapse loss and gliosis progress in an Alzheimer\u2019s mouse model after amyloid-\u03b2 immunotherapy"],"prefix":"10.1093","volume":"148","author":[{"given":"Lindsay A","family":"Welikovitch","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]},{"name":"Harvard Medical School , Harvard University, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasie","family":"Mate de Gerando","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]},{"name":"Harvard Medical School , Harvard University, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Khasnavis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshil","family":"Bhavsar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah C","family":"Meltzer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-4230","authenticated-orcid":false,"given":"Luc","family":"Bu\u00e9e","sequence":"additional","affiliation":[{"name":"University of Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition Lille , F-59000 Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-806X","authenticated-orcid":false,"given":"Lori B","family":"Chibnik","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bussiere","sequence":"additional","affiliation":[{"name":"Research and Development, Biogen , Cambridge, MA 02142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T","family":"Hyman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]},{"name":"Harvard Medical School , Harvard University, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2025040316585704700_awae345-B1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"2025040316585704700_awae345-B2","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"2025040316585704700_awae345-B3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol Sci"},{"key":"2025040316585704700_awae345-B4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/354432a0","article-title":"Alzheimer\u2019s disease. In the beginning","volume":"354","author":"Selkoe","year":"1991","journal-title":"Nature"},{"key":"2025040316585704700_awae345-B5","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain"},{"key":"2025040316585704700_awae345-B6","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.ajpath.2017.03.011","article-title":"Enhanced tau aggregation in the presence of amyloid \u03b2","volume":"187","author":"Bennett","year":"2017","journal-title":"Am J Pathol"},{"issue":"3 Pt 1","key":"2025040316585704700_awae345-B7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"2025040316585704700_awae345-B8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease","volume":"41","author":"G\u00f3mez-Isla","year":"1997","journal-title":"Ann Neurol"},{"key":"2025040316585704700_awae345-B9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"2025040316585704700_awae345-B10","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease. Reply","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2025040316585704700_awae345-B11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"2025040316585704700_awae345-B12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A\u03b2 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"2025040316585704700_awae345-B13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A\u03b2 peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"2025040316585704700_awae345-B14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/85525","article-title":"Imaging of amyloid-\u03b2 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy","volume":"7","author":"Bacskai","year":"2001","journal-title":"Nat Med"},{"key":"2025040316585704700_awae345-B15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2353\/ajpath.2006.060002","article-title":"Alzheimer\u2019s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits","volume":"169","author":"Schindowski","year":"2006","journal-title":"Am J Pathol"},{"key":"2025040316585704700_awae345-B16","first-page":"838","article-title":"Screening for amyloid aggregation by semi-denaturing detergent-agarose gel electrophoresis","volume":"17","author":"Halfmann","year":"2008","journal-title":"J Vis Exp"},{"key":"2025040316585704700_awae345-B17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","article-title":"Distinct tau prion strains propagate in cells and mice and define different tauopathies","volume":"82","author":"Sanders","year":"2014","journal-title":"Neuron"},{"key":"2025040316585704700_awae345-B18","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1093\/brain\/awy117","article-title":"Tau reduction in the presence of amyloid-\u03b2 prevents tau pathology and neuronal death in vivo","volume":"141","author":"DeVos","year":"2018","journal-title":"Brain"},{"key":"2025040316585704700_awae345-B19","doi-asserted-by":"crossref","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","article-title":"Proteopathic tau seeding predicts tauopathy in vivo","volume":"111","author":"Holmes","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040316585704700_awae345-B20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00401-023-02600-1","article-title":"Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tau","volume":"146","author":"Mate De Gerando","year":"2023","journal-title":"Acta Neuropathol"},{"key":"2025040316585704700_awae345-B21","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"Qupath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2025040316585704700_awae345-B22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40478-015-0199-x","article-title":"Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer\u2019s disease","volume":"3","author":"Pooler","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"2025040316585704700_awae345-B23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40478-016-0336-1","article-title":"Increased tauopathy drives microglia-mediated clearance of beta-amyloid","volume":"4","author":"Chen","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"2025040316585704700_awae345-B24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-022-00589-x","article-title":"Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes","volume":"17","author":"Kim","year":"2022","journal-title":"Mol Neurodegener"},{"key":"2025040316585704700_awae345-B25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat Neurosci"},{"key":"2025040316585704700_awae345-B26","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","article-title":"Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease","volume":"26","author":"Dujardin","year":"2020","journal-title":"Nat Med"},{"key":"2025040316585704700_awae345-B27","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/j.1460-2075.1995.tb07116.x","article-title":"Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform","volume":"14","author":"G\u00f6tz","year":"1995","journal-title":"EMBO J"},{"key":"2025040316585704700_awae345-B28","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1523\/JNEUROSCI.16-14-04491.1996","article-title":"Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer\u2019s disease","volume":"16","author":"G\u00f3mez-Isla","year":"1996","journal-title":"J Neurosci"},{"key":"2025040316585704700_awae345-B29","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/archneurol.2011.70","article-title":"Amyloid-dependent and amyloid-independent stages of Alzheimer disease","volume":"68","author":"Hyman","year":"2011","journal-title":"Arch Neurol"},{"key":"2025040316585704700_awae345-B30","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1126\/science.adj9255","article-title":"Immunotherapies for Alzheimer\u2019s disease","volume":"382","author":"Golde","year":"2023","journal-title":"Science"},{"key":"2025040316585704700_awae345-B31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature"},{"key":"2025040316585704700_awae345-B32","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41591-022-01926-9","article-title":"Anti-inflammatory clearance of amyloid-\u03b2 by a chimeric gas6 fusion protein","volume":"28","author":"Jung","year":"2022","journal-title":"Nat Med"},{"key":"2025040316585704700_awae345-B33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-022-01273-8","article-title":"Fc effector of anti-A\u03b2 antibody induces synapse loss and cognitive deficits in Alzheimer\u2019s disease-like mouse model","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025040316585704700_awae345-B34","doi-asserted-by":"crossref","first-page":"eabd7522","DOI":"10.1126\/scitranslmed.abd7522","article-title":"APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function","volume":"13","author":"Xiong","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awae345\/60455833\/awae345.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/4\/1316\/60455833\/awae345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/4\/1316\/60455833\/awae345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:43:05Z","timestamp":1743720185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/4\/1316\/7879565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,6]]},"published-print":{"date-parts":[[2025,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awae345","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,11,6]]}}}